A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial
The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.
• Has childhood apraxia of speech
• Aged 6-12 years
• Can perform the speech tasks for the trial (able to speak single words and short sentences)
• English as a first language
• Has adequate hearing
• Has a legally acceptable representative capable of understanding the informed consent document and providing consent on their behalf
• Passes the health and medical examination including examination of heart rate and blood pressure for age and weight norms
• Can commit to the time requirements of the trial
• Lives within 250 kilometres of the study site (MCRI)
• Able to swallow a capsule
• Scores 13 or more out of 27 on either the inattention and/or hyperactivity subscales of the SNAP-IV Parent 18-Item Rating Scale, suggesting clinically significant symptoms of inattention and/or hyperactivity